https://wikimd.com/index.php?action=history&feed=atom&title=Bleomycin_hydrolaseBleomycin hydrolase - Revision history2026-04-20T10:00:02ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.com/index.php?title=Bleomycin_hydrolase&diff=5406807&oldid=prevPrab: CSV import2024-03-17T19:56:10Z<p>CSV import</p>
<p><b>New page</b></p><div>'''Bleomycin hydrolase''' ('''BLMH''') is an enzyme that in humans is encoded by the ''BLMH'' gene. This enzyme plays a crucial role in the metabolism of [[bleomycin]], a glycopeptide [[antibiotic]] commonly used in the treatment of various types of [[cancer]], including [[Hodgkin's lymphoma]], [[testicular cancer]], and certain types of [[head and neck cancer]]. Bleomycin hydrolase is a [[cysteine peptidase]] that belongs to the family of [[hydrolases]], enzymes that catalyze the hydrolysis of chemical bonds.<br />
<br />
== Function ==<br />
Bleomycin hydrolase is a [[homohexamer]] that is ubiquitously expressed in human tissues. It has a broad substrate specificity, including the ability to inactivate bleomycin by hydrolyzing its terminal amine. This inactivation is crucial for limiting the drug's toxicity to healthy cells during cancer treatment. Beyond its role in drug metabolism, bleomycin hydrolase is involved in various physiological processes, including [[protein turnover]], [[apoptosis]], and the regulation of [[cytokine]] production. It also plays a role in the maintenance of [[epidermal]] homeostasis and has been implicated in the pathogenesis of [[Alzheimer's disease]] due to its ability to degrade amyloid peptides.<br />
<br />
== Clinical Significance ==<br />
The activity of bleomycin hydrolase can significantly affect the efficacy and toxicity of bleomycin therapy. Variations in the ''BLMH'' gene have been associated with differences in patient responses to bleomycin, including susceptibility to bleomycin-induced [[pulmonary fibrosis]], a severe side effect of the drug. Understanding the genetic and biochemical factors that influence bleomycin hydrolase activity is important for optimizing bleomycin therapy and minimizing its adverse effects.<br />
<br />
== Genetic Aspects ==<br />
The ''BLMH'' gene is located on chromosome 17q11.2 and consists of 10 exons. Polymorphisms in this gene have been studied for their potential impact on the enzyme's function and the clinical outcomes of bleomycin treatment. Research in this area aims to identify genetic markers that could predict patient sensitivity to bleomycin and guide personalized cancer therapy.<br />
<br />
== Research Directions ==<br />
Ongoing research is exploring the broader biological functions of bleomycin hydrolase, including its role in immune regulation and its potential as a therapeutic target in diseases characterized by abnormal protein aggregation, such as Alzheimer's disease. Additionally, studies are investigating the enzyme's structure and mechanism of action to design inhibitors that could enhance bleomycin's therapeutic window by selectively protecting healthy tissues from drug toxicity.<br />
<br />
== See Also ==<br />
* [[Cancer]]<br />
* [[Chemotherapy]]<br />
* [[Enzyme]]<br />
* [[Genetic polymorphism]]<br />
* [[Protein degradation]]<br />
<br />
== References ==<br />
<references/><br />
<br />
[[Category:Enzymes]]<br />
[[Category:Human proteins]]<br />
[[Category:Cancer treatment]]<br />
{{medicine-stub}}</div>Prab